vs
CSW INDUSTRIALS, INC.（CSW）とVERACYTE, INC.（VCYT）の財務データ比較。上の社名をクリックして会社を切り替えられます
CSW INDUSTRIALS, INC.の直近四半期売上が大きい（$233.0M vs $140.6M、VERACYTE, INC.の約1.7倍）。VERACYTE, INC.の純利益率が高く（29.3% vs 4.4%、差は24.9%）。CSW INDUSTRIALS, INC.の前年同期比売上増加率が高い（20.3% vs 18.5%）。VERACYTE, INC.の直近四半期フリーキャッシュフローが多い（$48.8M vs $22.7M）。過去8四半期でVERACYTE, INC.の売上複合成長率が高い（20.5% vs 5.1%）
ベラサイト社は、がんやその他の複雑な疾患の早期かつ正確な検出を目的とした独自のゲノム検査ソリューションを開発・販売する分子診断分野のリーディングカンパニーです。主に米国を中心に事業を展開し、医療従事者の臨床判断支援と患者の予後向上に貢献する製品を提供し、国際展開も加速させています。
CSW vs VCYT — 直接比較
売上が大きい
CSW
1.7倍大きい
$140.6M
売上成長率が高い
CSW
+1.8%の差
18.5%
純利益率が高い
VCYT
純利益率が24.9%高い
4.4%
フリーキャッシュフローが多い
VCYT
FCF $26.1M多い
$22.7M
2年売上CAGRが高い
VCYT
2年複合成長率
5.1%
損益計算書 — Q3 FY2026 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $233.0M | $140.6M |
| 純利益 | $10.3M | $41.1M |
| 粗利率 | 39.7% | 72.5% |
| 営業利益率 | 7.4% | 26.4% |
| 純利益率 | 4.4% | 29.3% |
| 売上前年比 | 20.3% | 18.5% |
| 純利益前年比 | -61.9% | 704.8% |
| EPS（希薄化後） | $0.62 | $0.50 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
売上CSWVCYT
| Q4 25 | $233.0M | $140.6M | ||
| Q3 25 | $277.0M | $131.9M | ||
| Q2 25 | $263.6M | $130.2M | ||
| Q1 25 | $230.5M | $114.5M | ||
| Q4 24 | $193.6M | $118.6M | ||
| Q3 24 | $227.9M | $115.9M | ||
| Q2 24 | $226.2M | $114.4M | ||
| Q1 24 | $210.9M | $96.8M |
純利益CSWVCYT
| Q4 25 | $10.3M | $41.1M | ||
| Q3 25 | $40.7M | $19.1M | ||
| Q2 25 | $40.9M | $-980.0K | ||
| Q1 25 | $35.1M | $7.0M | ||
| Q4 24 | $26.9M | $5.1M | ||
| Q3 24 | $36.1M | $15.2M | ||
| Q2 24 | $38.6M | $5.7M | ||
| Q1 24 | $31.8M | $-1.9M |
粗利率CSWVCYT
| Q4 25 | 39.7% | 72.5% | ||
| Q3 25 | 43.0% | 69.2% | ||
| Q2 25 | 43.8% | 69.0% | ||
| Q1 25 | 44.2% | 69.5% | ||
| Q4 24 | 41.4% | 66.4% | ||
| Q3 24 | 45.6% | 68.2% | ||
| Q2 24 | 47.5% | 68.1% | ||
| Q1 24 | 44.4% | 64.5% |
営業利益率CSWVCYT
| Q4 25 | 7.4% | 26.4% | ||
| Q3 25 | 20.5% | 17.4% | ||
| Q2 25 | 20.8% | -4.0% | ||
| Q1 25 | 19.5% | 2.5% | ||
| Q4 24 | 15.3% | 3.5% | ||
| Q3 24 | 22.6% | 10.4% | ||
| Q2 24 | 24.3% | 4.0% | ||
| Q1 24 | 21.0% | -4.8% |
純利益率CSWVCYT
| Q4 25 | 4.4% | 29.3% | ||
| Q3 25 | 14.7% | 14.5% | ||
| Q2 25 | 15.5% | -0.8% | ||
| Q1 25 | 15.2% | 6.2% | ||
| Q4 24 | 13.9% | 4.3% | ||
| Q3 24 | 15.8% | 13.1% | ||
| Q2 24 | 17.1% | 5.0% | ||
| Q1 24 | 15.1% | -1.9% |
EPS（希薄化後）CSWVCYT
| Q4 25 | $0.62 | $0.50 | ||
| Q3 25 | $2.41 | $0.24 | ||
| Q2 25 | $2.43 | $-0.01 | ||
| Q1 25 | $2.05 | $0.09 | ||
| Q4 24 | $1.60 | $0.07 | ||
| Q3 24 | $2.26 | $0.19 | ||
| Q2 24 | $2.47 | $0.07 | ||
| Q1 24 | $2.03 | $-0.02 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $40.2M | $362.6M |
| 総負債低いほど良い | — | — |
| 株主資本純資産 | $1.1B | $1.3B |
| 総資産 | $2.3B | $1.4B |
| 負債/資本比率低いほどレバレッジが低い | — | — |
8四半期トレンド — 暦四半期で整列
現金・短期投資CSWVCYT
| Q4 25 | $40.2M | $362.6M | ||
| Q3 25 | $31.5M | $315.6M | ||
| Q2 25 | $38.0M | $219.5M | ||
| Q1 25 | $225.8M | $186.1M | ||
| Q4 24 | $213.8M | $239.1M | ||
| Q3 24 | $273.2M | $274.1M | ||
| Q2 24 | $18.9M | $235.9M | ||
| Q1 24 | $22.2M | $209.2M |
総負債CSWVCYT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $800.1M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $166.0M | — |
株主資本CSWVCYT
| Q4 25 | $1.1B | $1.3B | ||
| Q3 25 | $1.1B | $1.3B | ||
| Q2 25 | $1.1B | $1.2B | ||
| Q1 25 | $1.1B | $1.2B | ||
| Q4 24 | $1.0B | $1.2B | ||
| Q3 24 | $1.0B | $1.2B | ||
| Q2 24 | $650.2M | $1.1B | ||
| Q1 24 | $615.7M | $1.1B |
総資産CSWVCYT
| Q4 25 | $2.3B | $1.4B | ||
| Q3 25 | $1.5B | $1.4B | ||
| Q2 25 | $1.5B | $1.3B | ||
| Q1 25 | $1.4B | $1.3B | ||
| Q4 24 | $1.4B | $1.3B | ||
| Q3 24 | $1.4B | $1.3B | ||
| Q2 24 | $1.1B | $1.2B | ||
| Q1 24 | $1.0B | $1.2B |
負債/資本比率CSWVCYT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.75× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.27× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $28.9M | $52.6M |
| フリーキャッシュフロー営業CF - 設備投資 | $22.7M | $48.8M |
| FCFマージンFCF / 売上 | 9.8% | 34.7% |
| 設備投資強度設備投資 / 売上 | 2.6% | 2.7% |
| キャッシュ転換率営業CF / 純利益 | 2.81× | 1.28× |
| 直近12ヶ月FCF直近4四半期 | $162.0M | $126.6M |
8四半期トレンド — 暦四半期で整列
営業キャッシュフローCSWVCYT
| Q4 25 | $28.9M | $52.6M | ||
| Q3 25 | $61.8M | $44.8M | ||
| Q2 25 | $60.6M | $33.6M | ||
| Q1 25 | $27.3M | $5.4M | ||
| Q4 24 | $11.6M | $24.5M | ||
| Q3 24 | $66.8M | $30.0M | ||
| Q2 24 | $62.7M | $29.6M | ||
| Q1 24 | $22.4M | $-9.0M |
フリーキャッシュフローCSWVCYT
| Q4 25 | $22.7M | $48.8M | ||
| Q3 25 | $58.7M | $42.0M | ||
| Q2 25 | $57.7M | $32.3M | ||
| Q1 25 | $22.8M | $3.5M | ||
| Q4 24 | $8.5M | $20.4M | ||
| Q3 24 | $61.3M | $27.7M | ||
| Q2 24 | $59.6M | $26.8M | ||
| Q1 24 | $17.5M | $-11.1M |
FCFマージンCSWVCYT
| Q4 25 | 9.8% | 34.7% | ||
| Q3 25 | 21.2% | 31.8% | ||
| Q2 25 | 21.9% | 24.8% | ||
| Q1 25 | 9.9% | 3.1% | ||
| Q4 24 | 4.4% | 17.2% | ||
| Q3 24 | 26.9% | 23.9% | ||
| Q2 24 | 26.3% | 23.4% | ||
| Q1 24 | 8.3% | -11.5% |
設備投資強度CSWVCYT
| Q4 25 | 2.6% | 2.7% | ||
| Q3 25 | 1.1% | 2.1% | ||
| Q2 25 | 1.1% | 1.0% | ||
| Q1 25 | 2.0% | 1.6% | ||
| Q4 24 | 1.6% | 3.5% | ||
| Q3 24 | 2.4% | 1.9% | ||
| Q2 24 | 1.4% | 2.4% | ||
| Q1 24 | 2.3% | 2.2% |
キャッシュ転換率CSWVCYT
| Q4 25 | 2.81× | 1.28× | ||
| Q3 25 | 1.52× | 2.34× | ||
| Q2 25 | 1.48× | — | ||
| Q1 25 | 0.78× | 0.76× | ||
| Q4 24 | 0.43× | 4.80× | ||
| Q3 24 | 1.85× | 1.98× | ||
| Q2 24 | 1.62× | 5.16× | ||
| Q1 24 | 0.71× | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
CSW
| Contractor Solutions Segment | $166.3M | 71% |
| Specialized Reliability Solutions Segment | $38.2M | 16% |
| Engineered Building Solutions Segment | $28.5M | 12% |
VCYT
| Testing | $135.8M | 97% |
| Products | $3.8M | 3% |
| Biopharmaceutical And Other | $686.0K | 0% |
